Alginate‐based microcapsules containing SeC (MC‐SeC) have been successfully employed as a single intraperitoneal (ip) injection in experimental models of type 1 and type 2 diabetes, acute hepatic failure, skin graft and Huntington’s disease.15, 16, 17, 18, 19, 20, 21 In an animal model reproducing the human Laron syndrome, in which mutations in the growth hormone receptor (GHR) lead to reduced production of IGF‐1 and subsequent dwarfism, intraperitoneally injected MC‐SeC promoted body growth through the release of IGF‐1 into the circulation.22 Here, GHR is linked to Acute hepatic failure.